Miao J, Bachmann KN, Huang S, et al. - In this prespecified, secondary analysis of the DAYLIGHT (Vitamin D Therapy in Individuals at High Risk of Hypertension) randomized controlled trial, researchers investigated if biomarkers of insulin resistance, inflammation, neurohormonal activation, and lipids could be decreased by vitamin D supplementation. Among 289 people with low vitamin D status (25‐hydroxyvitamin‐D ≤ 25 ng/mL) taking low‐dose (400 IU/d) vs high‐dose (4000 IU/d) vitamin D3 for 6 months, assessments were performed at baseline and at 6 months. According to the findings in the DAYLIGHT randomized controlled trial, no improvement in the biomarkers of glycemia, inflammation, neurohormonal activation, or lipids was conferred by high‐dose vitamin D supplementation.